产品名称	FTC-133人滤泡状甲状腺癌细胞
货号	ZQ0886
产品介绍	FTC-133细胞源自一名42岁患有滤泡状甲状腺癌的男性的淋巴结转移灶，具备侵袭和转移的能力。 该细胞系保留了分化的甲状腺细胞特征，表现出多种形态学和功能特性。 FTC-133细胞对甲状腺素和局部生长因子具有敏感反应。甲状腺球蛋白在细胞质中可见，保留了甲状腺激素合成功能。EGF受体表达。该细胞还存在p53基因突变，是细胞癌变的重要因素。该细胞系已用于研究人类甲状腺功能和甲状腺癌的发展。
种属	人
性别/年龄	男/42岁
组织	甲状腺(淋巴结转移)
疾病	滤泡性甲状腺癌
细胞类型	肿瘤细胞
形态学	上皮的
生长方式	贴壁
倍增时间	大约48~72小时
培养基和添加剂	RPMI-1640（中乔新舟 货号：ZQ-200）+10%胎牛血清（中乔新舟 货号：ZQ0500）+1%P/S（中乔新舟  货号：CSP006）
推荐完全培养基货号	ZM0886
生物安全等级	BSL-2
STR位点信息	Amelogenin：X； CSF1PO：10,10； D12S391：21,22； D13S317：11,11； D16S539：11,11； D18S51：11,11； D19S433：12,13； D21S11：32.2,32.2； D2S1338：20,20； D3S1358：15,15； D5S818：12,12； D6S1043：19,19； D7S820：9,10； D8S1179：10,10； FGA：21,21； Penta E：13,13； TH01：9.3,9.3； TPOX：9,9； vWA：15,18；
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达	***
基因表达	***
保藏机构	ECACC 94060901
供应限制	仅供科研使用

货号	ZQ0886
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma
DOI： 10.1111/1759-7714.13270
发表时间： 2019-12-10
期刊： Thoracic Cancer
影响因子： 2.524
货号： ZQ0886
产品名称： FTC-133 cell line

原文链接： https://onlinelibrary.wiley.com/doi/abs/10.1111/1759-7714.13270

PubMed=2247845
Demeure M.J., Hughes-Fulford M.E., Goretzki P.E., Duh Q.-Y., Clark O.H.
Actin architecture of cultured human thyroid cancer cells: predictor of differentiation?
Surgery 108:986-992(1990)

PubMed=1726925
Gerber H., Peter H.-J., Asmis L., Studer H.
Thyroid cell lines in research on goitrogenesis.
Thyroidology 3:115-118(1991)

PubMed=1384245; DOI=10.1007/BF02067383
Demeure M.J., Damsky C.H., Elfman F., Goretzki P.E., Wong M.G., Clark O.H.
Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases.
World J. Surg. 16:770-776(1992)

PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)

PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026
van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.
Cancer Res. 67:8113-8120(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23162534; DOI=10.3389/fendo.2012.00133
Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.
Thyroid cancer cell lines: an overview.
Front. Endocrinol. 3:133.1-133.9(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)